semaglutide producers Obesity FDA Warns on Certain Forms

A 2025 meta-analysis reviewed results from 20 clinical trials with 18,231 participants who took semaglutide injections

Regulatory agencies should carefully review the safety data for GLP-1 receptor agonists and consider requiring additional warnings and precautions on drug labels

Susan Mollan, a consultant neuro-ophthalmologist at the University Hospitals Birmingham in the United Kingdom, wrote in an email that past trials in people with diabetes have shown that when a patients blood sugar control is tightened, they may have a paradoxical worsening of their diabetic retinopathy (temporarily), so its plausible that the GLP-1 drugs, which also help control blood sugar, could have a paradoxical biological effect. Mollan wrote an editorial that was published alongside the new study

We will cover that in detail below

The safety information below is the documented drug-label class information, reproduced as reference

I pair incomplete proteins to create complete amino acid profiles hemp hearts in my yogurt, or a small portion of quinoa with my black bean soup